REPL
Price
$9.78
Change
-$0.11 (-1.11%)
Updated
Jun 13 closing price
Capitalization
753.91M
46 days until earnings call
SRPT
Price
$36.18
Change
-$1.13 (-3.03%)
Updated
Jun 13 closing price
Capitalization
3.56B
45 days until earnings call
Interact to see
Advertisement

REPL vs SRPT

Header iconREPL vs SRPT Comparison
Open Charts REPL vs SRPTBanner chart's image
Replimune Group
Price$9.78
Change-$0.11 (-1.11%)
Volume$680.24K
Capitalization753.91M
Sarepta Therapeutics
Price$36.18
Change-$1.13 (-3.03%)
Volume$3.2M
Capitalization3.56B
REPL vs SRPT Comparison Chart
Loading...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
REPL vs. SRPT commentary
Jun 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REPL is a Hold and SRPT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2025
Stock price -- (REPL: $9.78 vs. SRPT: $36.18)
Brand notoriety: REPL: Not notable vs. SRPT: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REPL: 54% vs. SRPT: 79%
Market capitalization -- REPL: $753.91M vs. SRPT: $3.56B
REPL [@Biotechnology] is valued at $753.91M. SRPT’s [@Biotechnology] market capitalization is $3.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REPL’s FA Score shows that 1 FA rating(s) are green whileSRPT’s FA Score has 0 green FA rating(s).

  • REPL’s FA Score: 1 green, 4 red.
  • SRPT’s FA Score: 0 green, 5 red.
According to our system of comparison, REPL is a better buy in the long-term than SRPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REPL’s TA Score shows that 7 TA indicator(s) are bullish while SRPT’s TA Score has 4 bullish TA indicator(s).

  • REPL’s TA Score: 7 bullish, 3 bearish.
  • SRPT’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, REPL is a better buy in the short-term than SRPT.

Price Growth

REPL (@Biotechnology) experienced а -5.78% price change this week, while SRPT (@Biotechnology) price change was -15.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.

Reported Earning Dates

REPL is expected to report earnings on Jul 31, 2025.

SRPT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (-0.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SRPT($3.56B) has a higher market cap than REPL($754M). REPL YTD gains are higher at: -19.240 vs. SRPT (-70.244). SRPT has higher annual earnings (EBITDA): -106.51M vs. REPL (-235.43M). SRPT has more cash in the bank: 523M vs. REPL (484M). REPL has less debt than SRPT: REPL (76.2M) vs SRPT (1.34B). SRPT has higher revenues than REPL: SRPT (2.23B) vs REPL (0).
REPLSRPTREPL / SRPT
Capitalization754M3.56B21%
EBITDA-235.43M-106.51M221%
Gain YTD-19.240-70.24427%
P/E RatioN/A27.21-
Revenue02.23B-
Total Cash484M523M93%
Total Debt76.2M1.34B6%
FUNDAMENTALS RATINGS
REPL vs SRPT: Fundamental Ratings
REPL
SRPT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
66
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
4665
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for SRPT (66). This means that REPL’s stock grew somewhat faster than SRPT’s over the last 12 months.

REPL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SRPT (100). This means that REPL’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's SMR Rating (95) in the Biotechnology industry is in the same range as REPL (98). This means that SRPT’s stock grew similarly to REPL’s over the last 12 months.

REPL's Price Growth Rating (46) in the Biotechnology industry is in the same range as SRPT (65). This means that REPL’s stock grew similarly to SRPT’s over the last 12 months.

REPL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SRPT (100). This means that REPL’s stock grew similarly to SRPT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REPLSRPT
RSI
ODDS (%)
Bullish Trend 6 days ago
76%
Bullish Trend 3 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
75%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
77%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 19 days ago
77%
Bullish Trend 26 days ago
73%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 3 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
74%
Aroon
ODDS (%)
Bullish Trend 3 days ago
81%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGKPX26.44-0.13
-0.49%
Goldman Sachs Income Builder P
MSPTX15.44-0.18
-1.15%
Morgan Stanley Inst Global Insgt C
FNCMX246.67-3.22
-1.29%
Fidelity Nasdaq Composite Index
TLCYX19.43-0.28
-1.42%
Touchstone Large Cap Y
JUSPX15.85-0.30
-1.86%
JPMorgan US Small Company R3

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with SNDX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then SNDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
-1.06%
SNDX - REPL
51%
Loosely correlated
-3.94%
XNCR - REPL
49%
Loosely correlated
-2.55%
IDYA - REPL
48%
Loosely correlated
-0.45%
KYMR - REPL
47%
Loosely correlated
-0.70%
SRPT - REPL
45%
Loosely correlated
-3.03%
More

SRPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRPT has been loosely correlated with BPMUF. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if SRPT jumps, then BPMUF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRPT
1D Price
Change %
SRPT100%
-3.03%
BPMUF - SRPT
52%
Loosely correlated
N/A
AAVXF - SRPT
45%
Loosely correlated
N/A
ARWR - SRPT
44%
Loosely correlated
-2.96%
COGT - SRPT
43%
Loosely correlated
-1.94%
SNDX - SRPT
42%
Loosely correlated
-3.94%
More